Retrosynthetic Analysis Tools: What Medicinal Chemists Are Using in 2026

Three years ago retrosynthesis software was a niche tool used by maybe a dozen research groups. Now there are at least six serious options, the AI underneath them has changed twice, and the right pick for a medicinal chemist is genuinely different from the right pick for a process chemist or an academic exploring a new chemotype. The vendor websites all promise the same thing — better routes, faster — which is exactly when a practitioner has to read the actual decision boundaries past the marketing.

This post is a decision tree for picking retrosynthesis software for small-molecule drug design work. It covers the dimensions that actually separate the tools (training data, output format, integration), names the named options as of 2026, and flags the cases where the right answer is "none yet, draw the route yourself." Mechanism-aware retrosynthesis is covered in the reaction-mode post; this one is the broader picking-a-tool decision.

What retrosynthesis software actually does

Retrosynthesis is working backward from a target molecule to identify simpler precursors and the reactions that connect them. The classical version was Corey’s disconnection-approach — manual, paper-based, taught to every organic chemist. Software-assisted retrosynthesis automates the disconnection step: given a target SMILES (or drawn structure), the software proposes one or more synthetic routes, each as a tree of reactions back to commercially-available starting materials.

Modern tools differ in three load-bearing ways: where the reaction rules come from (hand-curated rules vs. learned from reaction databases vs. generative models), how routes are scored (cost, step count, predicted yield, stockroom availability), and what the output looks like (a single best route, a Pareto frontier, an interactive tree the chemist can prune).

Factors that determine which tool fits

Six dimensions matter when picking between options:

• Chemistry scope: does the tool cover medicinal chemistry well (amide coupling, Suzuki, reductive amination, deprotection sequences) or is it general-organic with thin med-chem coverage?
• Training data provenance: was the model trained on USPTO patents (broad, noisy), Reaxys (curated, expensive license), in-house data, or a public synthesis corpus? Provenance determines what kinds of routes the tool can suggest.
• Stockroom integration: can the tool prefer routes that use building blocks already in your inventory or your contract supplier’s catalog? Without this, the suggested route may require ordering 18 starting materials.
• Mechanism awareness: does the tool reason about reaction mechanisms (functional-group compatibility, protecting-group strategy, stereochemistry control) or just match structural transformations?
• Output transparency: can you see why the tool proposed a particular disconnection — literature references, similar reactions, confidence scores? Or is it a black-box suggestion?
• Deployment model: cloud-only (sends your structures to a vendor), on-premise (you host the model), or open-source (you run locally with no data leaving)?

The decision tree

Path 1 — sensitive structures, cannot leave your environment

If your structures are pre-publication, patent-sensitive, or contain proprietary scaffolds you cannot send to a cloud API, the choice narrows fast. The two practical options:

• Open-source on-premise: AiZynthFinder (AstraZeneca, MIT-licensed) is the leading open-source option. Runs locally, trained on USPTO data, configurable with custom building-block catalogs. Reasonable med-chem coverage. Trade-off: setup is non-trivial (Python environment, model download, building-block file curation) and the routes are USPTO-quality — broad but noisy.
• Enterprise on-premise: Synthia (Merck KGaA / Sigma-Aldrich), Chemical.AI on-premise, or the major ELN vendors’ on-prem deployments. These come with curated reaction databases (typically Reaxys-derived or vendor-curated), better med-chem coverage, and stockroom integration. Trade-off: enterprise pricing and procurement timeline.

If you are at a small biotech or academic group, AiZynthFinder is usually the right starting point. The setup pays for itself across the next 50 routes you plan. If you are at a pharma with established Reaxys access and an IT budget, the enterprise on-prem options give you better route quality without the curation work.

Path 2 — cloud is acceptable, med chem is the focus

If structures can leave your environment, the cloud options expand the field. The decision then turns on med-chem specialization:

• Med-chem-tuned cloud tools: IBM RXN for Chemistry (free tier available, Reaxys-trained variant for enterprise), Chemical.AI cloud, the major CRO platforms (Schrödinger, OpenEye). These tools have explicit med-chem training and stockroom integration with commercial catalog providers (Enamine, Sigma, etc.).
• General-organic cloud tools: ASKCOS (MIT, open + cloud), the standalone academic retrosynthesis demos. Lighter on med-chem-specific reactions but transparent about training data and confidence scores.

For SAR-series planning where you need 20 analogs synthesized fast, a med-chem-tuned tool with stockroom integration usually wins on practical throughput. For a single complex target where you want to understand the route options deeply before committing, ASKCOS or AiZynthFinder give you the transparency to read the disconnections yourself.

Path 3 — you need the route to integrate with an existing ELN workflow

If your group runs Benchling, Signals Notebook, or Dotmatics for experiment recording, the retrosynthesis tool that integrates with that ELN often beats a better standalone tool that lives outside the workflow. ELN-integrated retrosynthesis is most mature for Dotmatics (acquired Symmetry Labs) and Benchling (partner integrations); Signals Notebook is moving in this direction with Revvity’s acquisition portfolio.

The integration gain is structural: a route proposed in the tool, reviewed by the chemist, and converted to ELN reaction entries is one workflow step. A route proposed in a standalone tool, copied as SMILES, re-drawn in the ELN, and re-recorded as reactions is three workflow steps and three chances to introduce a transcription error. For groups doing more than 10 routes per week, the integration tax adds up.

Path 4 — the route is short and you should draw it yourself

Retrosynthesis software is most useful when the target is structurally novel, the route is non-obvious, or the candidate count is high enough that automation pays off. For a 2-step amide coupling on a known scaffold, software is overkill — an experienced medicinal chemist sees the disconnection in seconds, and the tool’s top suggestion will be the same disconnection plus 5 inferior alternatives the chemist has to filter through.

Practical heuristic: if you can write the disconnection on a napkin in under 30 seconds, draw the route yourself. If the target makes you reach for the literature or you cannot see a clean disconnection, that is the right moment for software.

Summary table

What to watch for in 2026 evaluations

Three signals to weight when evaluating any retrosynthesis tool:

• Route diversity vs. route quality: tools that suggest 20 routes are not better than tools that suggest 3 good routes. Ask for the Pareto frontier — the routes that are not dominated on cost, step count, and predicted feasibility. Vendors that only show you a top-1 suggestion are hiding information you need.
• Stockroom catalog refresh frequency: a tool that uses 2022 Enamine catalog data will suggest building blocks that may no longer be in stock. Ask when the building-block catalog was last refreshed and how often it updates.
• Stereochemistry handling in suggestions: ask the tool to suggest a route to a single enantiomer of a chiral target. If the tool ignores stereochemistry or proposes routes that produce racemates, it is not med-chem-ready — chirality control is load-bearing for drug candidates.

The space is moving fast. Tools that were competitive a year ago may not be in the running now, and the academic-cloud-free options have closed a lot of the gap on commercial tools for general-organic retrosynthesis. The med-chem-specific gap (curated reaction data + stockroom integration + mechanism awareness) is what enterprise tools still lead on.

Trying retrosynthesis in your workflow

For most medicinal chemists, the practical entry point is one of the free or freemium cloud tools (IBM RXN free tier, ASKCOS, AiZynthFinder running locally on a workstation). Run a target you have already synthesized through the tool and see how close the top suggestion comes to your actual route. That comparison tells you more about the tool’s fit for your chemistry than any benchmark on the vendor website.

ChemStitch’s reaction mode supports drawing the proposed routes from any retrosynthesis tool and computing molecular properties, atom economy, and reagent tables for each step — converting the route into the form the bench needs. The retrosynthesis tool gives you the disconnection; the editor and the green-chemistry metrics tell you which proposed route is worth running.